Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy-Reference-Cited by-同舟云学术

Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy

Published:2015-03-24 Issue:10 Volume:26 Page:2545-2558
ISSN:1046-6673
Container-title:Journal of the American Society of Nephrology
language:en
Short-container-title:JASN

Author:

Ruggenenti Piero,Debiec Hanna,Ruggiero Barbara,Chianca Antonietta,Pellé Timothee,Gaspari Flavio,Suardi Flavio,Gagliardini Elena,Orisio Silvia,Benigni Ariela,Ronco Pierre,Remuzzi Giuseppe

Publisher

American Society of Nephrology (ASN)

Subject

Nephrology,General Medicine

Reference32 articles.

1. Rituximab for idiopathic membranous nephropathy

2. Rituximab Therapy for Membranous Nephropathy: A Systematic Review

3. Efficacy and Safety of Rituximab Second-Line Therapy for Membranous Nephropathy: A Prospective, Matched-Cohort Study

4. Successful Treatment of Membranous Glomerulonephritis with Rituximab in Calcineurin Inhibitor-Dependent Patients

5. Rituximab in Idiopathic Membranous Nephropathy

Cited by 291 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination therapy with rituximab and low dose cyclophosphamide and prednisone in membranous nephropathy;Kidney International Reports;2024-09

2. Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody–Positive Primary Membranous Nephropathy;Kidney International Reports;2024-09

3. Treatment of membranous nephropathy: a novel approach?;Nephrology Dialysis Transplantation;2024-08-10

4. Prognostic and therapeutic monitoring value of plasma and urinary cytokine profile in primary membranous nephropathy: the STARMEN trial cohort;Clinical Kidney Journal;2024-08-01

5. THSD7A-associated membranous nephropathy involves both complement-mediated and autonomous podocyte injury;Frontiers in Pharmacology;2024-07-17